selepressin

Selepressin is a potent, highly selective, short-acting peptide full agonist of the vasopressin 1A receptor (V1A). It is an analog of vasopressin developed by Ferring Pharmaceuticals for the treatment of vasodilatory hypotension in septic shock. Selepressin was designed to increase arterial pressure and potentially reduce vascular leakage and pulmonary edema in patients with septic shock. Clinical trials demonstrated that selepressin could rapidly replace norepinephrine, improve fluid balance, and shorten mechanical ventilation time in septic shock patients. However, its phase 2b/3 adaptive trial (SEPSIS-ACT) was terminated for futility before completion[1][4][5][7].

Other names

selepressin[Phe(2),Ile(3), Hgn(4),Orn(iPr)(8)]vasopressinH-Cys(1)-Phe-Ile-hGln-Asn-Cys(1)-Pro-Orn(iPr)-Gly-NH2